Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Pembrolizumab in Combination With Odetiglucan for Patients With Metastatic Colorectal Adenocarcinoma With Liver Predominant Disease

Next Previous
Trial Profile

Phase II Trial of Pembrolizumab in Combination With Odetiglucan for Patients With Metastatic Colorectal Adenocarcinoma With Liver Predominant Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Odetiglucan (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Cancer metastases; Colorectal cancer; Liver cancer
  • Focus Therapeutic Use

Most Recent Events

  • 22 Sep 2025 Status changed from not yet recruiting to recruiting.
  • 02 Sep 2025 Planned initiation date changed from 1 Jul 2025 to 1 Sep 2025.
  • 02 Sep 2025 Planned End Date changed from 1 Jul 2029 to 1 Sep 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top